CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 1,617.8	$ 1,467.7
Marketable securities	1,596.5	1,342.2
Accounts receivable - trade, net	2,100.0	1,723.7
Accounts receivable from Sanofi	260.6	226.4
Accounts receivable from Bayer	311.6	293.1
Inventories	1,415.5	1,151.2
Prepaid expenses and other current assets	387.1	243.3
Total current assets	7,689.1	6,447.6
Marketable securities	3,256.8	1,755.0
Property, plant, and equipment, net	2,890.4
Property, plant, and equipment, net		2,575.8
Deferred tax assets	824.2	828.7
Other noncurrent assets	144.7	127.4
Total assets	14,805.2	11,734.5
Current liabilities:
Accounts payable	418.1	218.2
Accrued expenses and other current liabilities	1,086.8	772.1
Deferred revenue, current	591.7	452.5
Total current liabilities	2,096.6	1,442.8
Finance lease liabilities	713.9
Finance lease liabilities		708.5
Deferred revenue, noncurrent	619.0	464.2
Other noncurrent liabilities	286.0	361.7
Total liabilities	3,715.5	2,977.2
Commitments and contingencies
Stockholders' equity:
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	0.0	0.0
Additional paid-in capital	4,428.6	3,911.6
Retained earnings	7,379.8	5,254.3
Accumulated other comprehensive income (loss)	21.1	(12.3)
Treasury Stock, at cost; 4,860,123 shares in 2019 and 3,990,021 shares in 2018	(739.9)	(396.4)
Total stockholders' equity	11,089.7	8,757.3
Total liabilities and stockholders' equity	14,805.2	11,734.5
Class A Stock
Stockholders' equity:
Common stock	0.0	0.0
Common Stock
Stockholders' equity:
Common stock	0.1	0.1
Total stockholders' equity	0.1	0.1
Sanofi
Current liabilities:
Deferred revenue, current	395.5	246.7
Deferred revenue, noncurrent	509.7	279.3
Other
Current liabilities:
Deferred revenue, current	196.2	205.8
Deferred revenue, noncurrent	$ 109.3	$ 184.9